Advertisement

Cardiovascular Drugs and Therapy

, Volume 32, Issue 1, pp 5–21 | Cite as

Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway

  • Kuixiang Chen
  • Mubarak Rekep
  • Wei Wei
  • Qian Wu
  • Qin Xue
  • Sujuan Li
  • Jiahui Tian
  • Quan Yi
  • Genshui Zhang
  • Guiping Zhang
  • Qing Xiao
  • Jiandong Luo
  • Yinghua Liu
ORIGINAL ARTICLE
  • 224 Downloads

Abstract

Purpose

Quercetin, a flavonoid, has been reported to ameliorate cardiovascular diseases, such as cardiac hypertrophy. However, the mechanism is not completely understood. In this study, a mechanism related to proteasome-glycogen synthesis kinase 3 (GSK-3) was elucidated in rats and primary neonatal cardiomyocytes.

Methods

Rats were subjected to sham or constriction of abdominal aorta surgery groups and treated with or without quercetin for 8 weeks. Angiotensin II (Ang II)-induced primary cardiomyocytes were cultured with quercetin treatment or not for 48 h. Echocardiography, real-time RT-PCR, histology, immunofluorescence, and Western blotting were conducted. Proteasome activities were also detected using a fluorescent peptide substrate.

Results

Echocardiography showed that quercetin prevented constriction of abdominal aorta-induced cardiac hypertrophy and improved the cardiac diastolic function. In addition, quercetin also significantly reduced the Ang II-induced hypertrophic surface area and atrial natriuretic factor (ANF) mRNA level in primary cardiomyocytes. Proteasome activities were obviously inhibited in the quercetin-treated group both in vivo and in vitro. Quercetin also decreased the levels of proteasome subunit beta type (PSMB) 1, PSMB2, and PSMB5 of the 20S proteasome as well as the levels of proteasome regulatory particle (Rpt) 1 and Rpt4 of the 19S proteasome. In particular, the PSMB5 level in the nucleus was reduced after quercetin treatment. Furthermore, phosphorylated GSK-3α/β (inactivation of GSK-3) was decreased, which means that GSK-3 activity was increased. The phosphorylation levels of upstream AKT (PKB (protein kinase B)) and liver kinase B1/AMP activated protein kinase (LKB1/AMPKα) and those of downstream extracellular signal-regulated kinase (ERK), histone H3, β-catenin, and GATA binding protein 4 (GATA4) were reduced after quercetin treatment, while hypertrophy was reversed after treatment with the GSK-3 inhibitor.

Conclusion

In summary, quercetin prevents cardiac hypertrophy, which is related to proteasome inhibition and activation of GSK-3α/β. Upstream (AKT, LKB1/AMPKα) and downstream hypertrophic factors, such as ERK, histone H3, β-catenin, and GATA4, may also be involved.

Keywords

Myocardial hypertrophy Quercetin Proteasome inhibition GSK-3 

Notes

Funding Information

This study was funded by grants from the National Natural Science Foundation of China (30901806 to YH. Liu), Natural Science Foundation of Guangdong Province (2014A030313485 to YH. Liu), Outstanding Young Teachers Training Plan in Higher Education Institutions of Guangdong Province (B16036028 to YH. Liu), Scientific and Technological Planning Program of Guangzhou (2017071010458 to YH. Liu), Municipal Education Bureau Program of Guangzhou (1201610286 to YH. Liu), Outstanding Young Teachers Training Plan in Higher Education Institutions of Guangdong Province (YQ2015137 to Q. Xue), Municipal Education Bureau Program of Guangzhou (1201410365 to Q. Xue), and Scientific and Technological Planning Program of Guangdong Province (2014A020212361, Q. Xiao).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures involving animal experimentation were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (USA). The animal use protocol was approved by the Committee on the Ethics of Animal Experiments of Guangzhou Medical University and the approval reference number was SCXK 2013-0002.

References

  1. 1.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360.CrossRefPubMedGoogle Scholar
  2. 2.
    Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, et al. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014;16(5):494–508.CrossRefPubMedGoogle Scholar
  3. 3.
    Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82(2):373–428.CrossRefPubMedGoogle Scholar
  4. 4.
    Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 1999;68(1):1015–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang X, Li J, Zheng H, Su H, Powell SR. Proteasome functional insufficiency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol. 2011;301(6):H2207–19.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Doll D, Sarikas A, Krajcik R, Zolk O. Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem Biophys Res Commun. 2007;353(2):436–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C, et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension. 2008;51(2):302–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Schlossarek S, Singh SR, Geertz B, Schulz H, Reischmann S, Hubner N, et al. Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy. Front Physiol. 2014;5:484.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Liu YH, Wei W, Yin J, Liu GP, Wang Q, Cao FY, et al. Proteasome inhibition increases tau accumulation independent of phosphorylation. Neurobiol Aging. 2009;30(12):1949–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhai P, Gao S, Holle E, Yu X, Yatani A, Wagner T, et al. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem. 2007;282(45):33181–91.CrossRefPubMedGoogle Scholar
  11. 11.
    Chen B, Wu Q, Xiong Z, Ma Y, Yu S, Chen D, et al. Adenosine monophosphate-activated protein kinase attenuates cardiomyocyte hypertrophy through regulation of FOXO3a/MAFbx signaling pathway. Acta Biochim Biophys Sin. 2016;48(9):827–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang L, Zhang S, Cheng H, Lv H, Cheng G, Ci X. Nrf2-mediated liver protection by esculentoside A against acetaminophen toxicity through the AMPK/Akt/GSK3beta pathway. Free Radic Biol Med. 2016;101:401–12.CrossRefPubMedGoogle Scholar
  13. 13.
    Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, et al. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis. 2011;218(1):44–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Yan L, Zhang JD, Wang B, Lv YJ, Jiang H, Liu GL, et al. Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-gamma expression and suppressing AP-1 activity. PLoS One. 2013;8(9):e72548.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ulasova E, Perez J, Hill BG, Bradley WE, Garber DW, Landar A, et al. Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse. Redox Biol. 2013;1(1):381–6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Han JJ, Hao J, Kim CH, Hong JS, Ahn HY, Lee YS. Quercetin prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Med Sci. 2009;71(6):737–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Qureshi AA, Tan X, Reis JC, Badr MZ, Papasian CJ, Morrison DC, et al. Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. Lipids Health Dis. 2011;10(1):177.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Barton CH, Ni Z, Vaziri ND. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int Rep. 2001;60(3):1083–7.CrossRefGoogle Scholar
  19. 19.
    Kobayashi S, Yano M, Kohno M, Obayashi M, Hisamatsu Y, Ryoke T, et al. Influence of aortic impedance on the development of pressure-overload left ventricular hypertrophy in rats. Circulation. 1996;94(12):3362–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Yang K, Zhang TP, Tian C, Jia LX, Du J, Li HH. Carboxyl terminus of heat shock protein 70-interacting protein inhibits angiotensin II-induced cardiac remodeling. Am J Hypert. 2012;25(9):994–1001.CrossRefGoogle Scholar
  21. 21.
    Samuel SM, Thirunavukkarasu M, Penumathsa SV, Koneru S, Zhan L, Maulik G, et al. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation. 2010;121(10):1244–55.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hou N, Cai B, Ou CW, Zhang ZH, Liu XW, Yuan M, et al. Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress. Naunyn Schmiedeberg’s Arch Pharmacol. 2017;390(5):535–45.CrossRefGoogle Scholar
  23. 23.
    Schumacher-Bass SM, Vesely ED, Zhang L, Ryland KE, McEwen DP, Chan PJ, et al. Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes. Circ Res. 2014;114(6):982–92.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Dosenko VE, Nagibin VS, Tumanovskaia LV, Zagorii V, Moibenko AA. The influence of quercetin on the activity of purified 20S, 26S proteasome and proteasomal activity in isolated cardiomyocytes. Biomed Khim. 2006;52(2):138–45.PubMedGoogle Scholar
  25. 25.
    Lal H, Ahmad F, Woodgett J, Force T. The GSK-3 family as therapeutic target for myocardial diseases. Circ Res. 2015;116(1):138–49.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res. 2002;90(10):1055–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Maejima Y, Galeotti J, Molkentin JD, Sadoshima J, Zhai P. Constitutively active MEK1 rescues cardiac dysfunction caused by overexpressed GSK-3alpha during aging and hemodynamic pressure overload. Am J Physiol Heart Circ Physiol. 2012;303(8):H979–88.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Arioka M, Takahashi-Yanaga F, Sasaki M, Yoshihara T, Morimoto S, Takashima A, et al. Acceleration of bone development and regeneration through the Wnt/beta-catenin signaling pathway in mice heterozygously deficient for GSK-3beta. Biochem Biophys Res Commun. 2013;440(4):677–82.CrossRefPubMedGoogle Scholar
  29. 29.
    Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol. 2011;51(4):607–13.CrossRefPubMedGoogle Scholar
  30. 30.
    Depre C, Powell SR, Wang X. The role of the ubiquitin-proteasome pathway in cardiovascular disease. Cardiovasc Res. 2010;85(2):251–2.CrossRefPubMedGoogle Scholar
  31. 31.
    Cacciapuoti F. Role of ubiquitin-proteasome system (UPS) in left ventricular hypertrophy (LVH). Am J Cardiovasc Dis. 2014;4(1):1–5.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Li N, Wang HX, Han QY, Li WJ, Zhang YL, Du J, et al. Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. J Mol Cell Cardiol. 2015;79:303–14.CrossRefPubMedGoogle Scholar
  33. 33.
    Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Antihypertensive effects of the flavonoid quercetin. Pharmacol Rep. 2009;61(1):67–75.CrossRefPubMedGoogle Scholar
  34. 34.
    Duarte J, Perez-Palencia R, Vargas F, Ocete MA, Perez-Vizcaino F, Zarzuelo A, et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol. 2001;133(1):117–24.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation. 2006;114(17):1821–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Klappan AK, Hones S, Mylonas I, Bruning A. Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity. Histochem Cell Biol. 2012;137(1):25–36.CrossRefPubMedGoogle Scholar
  37. 37.
    Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116(7):1175–86.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Lal H, Zhou J, Ahmad F, Zaka R, Vagnozzi RJ, Decaul M, et al. Glycogen synthase kinase-3alpha limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. Circulation. 2012;125(1):65–75.CrossRefPubMedGoogle Scholar
  39. 39.
    Blankesteijn WM, van de Schans VA, ter Horst P, Smits JF. The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol Sci. 2008;29(4):175–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Liu N, Chai R, Liu B, Zhang Z, Zhang S, Zhang J, et al. Ubiquitin-specific protease 14 regulates cardiac hypertrophy progression by increasing GSK-3beta phosphorylation. Biochem Biophys Res Commun. 2016;478(3):1236–41.CrossRefPubMedGoogle Scholar
  41. 41.
    Fan Y, Xie P, Zhang T, Zhang H, Gu D, She M, et al. Regulation of the stability and transcriptional activity of NFATc4 by ubiquitination. FEBS Lett. 2008;582(29):4008–14.CrossRefPubMedGoogle Scholar
  42. 42.
    Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol. 2005;17(2):150–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Shirwany NA, Zou MH. AMPK: a cellular metabolic and redox sensor. A Minireview Front Biosci. 2014;19(3):447–74.CrossRefGoogle Scholar
  44. 44.
    Ritho J, Arold ST, Yeh ET. A critical SUMO1 modification of LKB1 regulates AMPK activity during energy stress. Cell Rep. 2015;12(5):734–42.CrossRefPubMedGoogle Scholar
  45. 45.
    Luu BE, Tessier SN, Duford DL, Storey KB. The regulation of troponins I, C and ANP by GATA4 and Nkx2-5 in heart of hibernating thirteen-lined ground squirrels, Ictidomys tridecemlineatus. PloS one. 2015;10(2):e0117747.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Stubenvoll A, Rice M, Wietelmann A, Wheeler M, Braun T. Attenuation of Wnt/beta-catenin activity reverses enhanced generation of cardiomyocytes and cardiac defects caused by the loss of emerin. Hum Mol Genet. 2015;24(3):802–13.CrossRefPubMedGoogle Scholar
  47. 47.
    Lee H, Park J, Kim EE, Yoo YS, Song EJ. Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells. BMB Rep. 2016;49(5):270–5.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Bagul PK, Deepthi N, Sultana R, Banerjee SK. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. J Nutr Biochem. 2015;26(11):1298–307.CrossRefPubMedGoogle Scholar
  49. 49.
    Chen HP, Denicola M, Qin X, Zhao Y, Zhang L, Long XL, et al. HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome-dependent pathway. J Cell Biochem. 2011;112(11):3246–55.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Morrow KA, Das S, Meng E, Menezes ME, Bailey SK, Metge BJ, et al. Loss of tumor suppressor Merlin results in aberrant activation of Wnt/beta-catenin signaling in cancer. Oncotarget. 2016;7(14):17991–8005.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Kuixiang Chen
    • 1
    • 2
  • Mubarak Rekep
    • 1
  • Wei Wei
    • 3
  • Qian Wu
    • 1
  • Qin Xue
    • 1
  • Sujuan Li
    • 1
  • Jiahui Tian
    • 1
  • Quan Yi
    • 1
  • Genshui Zhang
    • 1
  • Guiping Zhang
    • 1
  • Qing Xiao
    • 1
  • Jiandong Luo
    • 1
  • Yinghua Liu
    • 1
  1. 1.Department of Pharmacology, School of Pharmaceutical SciencesGuangzhou Medical University, Key Laboratory of Molecular Clinical Pharmacology and Fifth Affiliated Hospital, Guangzhou Medical UniversityGuangzhouChina
  2. 2.Medical College of Jiaying UniversityMeizhouChina
  3. 3.Key Laboratory of State Administration of Traditional Chinese Medicine of China, Department of Pathophysiology, School of Medicine, Institute of Brain ResearchJinan UniversityGuangzhouChina

Personalised recommendations